Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Czech RSV shot study: will parents protect their babies?

NCT ID NCT07634692

Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 5 times

Summary

This study will observe how many eligible infants in Czechia receive nirsevimab, a monoclonal antibody that helps prevent RSV, during their first RSV season. Researchers will survey parents of about 250 infants born between April 2025 and March 2027 to understand immunization rates and reasons for or against the shot. No treatment is given—this is purely an observational study to gather real-world data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

257 people

The number who actually took part.

Started

Jun 2026

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will target a sample of 250 parents of infants born between April 2025 and March 2027. Eligible participants must be at least 18, reside in Czechia at the time of survey completion and speak Czech.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be a parent of an infant born between April 2025/26 and March 2026/27, respectively * Permanent residence in Czechia at the time of survey completion and speak Czech * Be at least 18 years old at the time of survey completion * Agree with privacy policy and AE (Adverse Event) reporting requirements before proceeding with the survey * Read and agree to the ICF (Informed Consent Form) by ticking a box before proceeding with the survey Exclusion criteria: * N/A The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RSV immunization are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RSV immunization

Contacts and locations

Locations

  • Sanofi s.r.o.

    Prague, 160 00, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.